Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the world of corporate finance, Selling, General, and Administrative (SG&A) expenses are a crucial indicator of a company's operational efficiency. This chart offers a fascinating comparison between Walgreens Boots Alliance, Inc. and Ionis Pharmaceuticals, Inc. over the past decade.

Walgreens Boots Alliance, Inc.

From 2014 to 2023, Walgreens Boots Alliance, Inc. consistently reported SG&A expenses in the range of $17.7 billion to $25.5 billion, reflecting its expansive retail operations. Notably, there was a 44% increase in expenses from 2014 to 2023, highlighting the company's growth and strategic investments.

Ionis Pharmaceuticals, Inc.

In contrast, Ionis Pharmaceuticals, Inc., a leader in RNA-targeted drug discovery, showed a more volatile trend. Starting at $20 million in 2014, their SG&A expenses peaked at $354 million in 2020, a staggering 1,670% increase, before stabilizing. This reflects their aggressive R&D and market expansion strategies.

Insights

While Walgreens' expenses indicate steady growth, Ionis' fluctuations underscore the dynamic nature of the biotech industry. Missing data for 2024 suggests ongoing developments worth watching.